The diabetes drug alogliptin did not appear to increase the odds of heart attack, stroke or cardiac death compared with placebo in type 2 diabetes patients with cardiovascular problems, a study in The New England Journal of Medicine revealed. Data on 5,380 patients showed 11.3% of those in the alogliptin arm died from heart problems or suffered a heart attack or stroke, compared with 11.8% of those who took a placebo.
Study: Alogliptin does not raise heart risk in diabetes
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||